Table 4 Crude and adjusted changes in utility indices for SARS-CoV-2 infected participants for all participants and for participants experiencing post-COVID symptoms, by time elapsed since testing.

Time elapsed since testing	Variables	All participants							Participants experiencing post-covid symptoms
	Vaccine doses	n	Univariate model			Adjusted			n	Crude analysis			Adjusted analysis
	Vaccine doses	n	Change in utility score	95% CI	p	Change in utility score	95% CI	p	n	Change in utility score	95% CI	p	Change in utility score	95% CI	p
3–6 months	Unvaccinated at the time of infection	118	Baseline						80	Baseline
	2-Doses	108	0.08	0.02–0.18	0.017	0.04	− 0.04–0.12	0.302	53	0.06	− 0.05–0.16	0.274	− 0.01	− 0.13–0.10	0.831
	3-Doses	217	0.09	0.03–0.14	0.005	0.03	− 0.04–0.10	0.396	128	0.11	0.02–0.19	0.012	0.05	− 0.05–0.14	0.325
	2 + 3 Doses	325	0.08	0.03–0.14	0.003	0.03	− 0.03–0.10	0.303	181	0.09	0.01–0.17	0.021	0.03	− 0.06–0.12	0.506
7–12 months	Unvaccinated at the time of infection	172	Baseline						109	Baseline
	2-Doses	48	0.03	− 0.06–0.12	0.540	0.11	− 0.01–0.22	0.063	35	0.10	− 0.03–0.23	0.123	0.17	0.03–0.31	0.017
	3-Doses	14	− 0.04	− 0.19–0.12	0.639	0.06	− 0.12–0.24	0.529	9	− 0.01	− 0.22– 0.21	0.963	0.06	− 0.17–0.30	0.593
	2 + 3 Doses	62	0.01	− 0.07–0.10	0.746	0.10	− 0.01–0.20	0.072	44	0.07	− 0.04–0.19	0.187	0.15	0.02–0.29	0.024
> 12 months	Unvaccinated at the time of infection	184	Baseline						109	Baseline
	2-Doses	71	0.01	− 0.08–0.11	0.765	0.06	− 0.06–0.17	0.348	39	0.04	− 0.09–0.17	0.505	0.05	− 0.07–0.16	0.410
	3-Doses	19	− 0.03	− 0.19–0.14	0.759	0.03	− 0.16–0.22	0.755	10	0.02	− 0.22–0.25	0.897	0.04	− 0.15–0.23	0.658
	2 + 3 Doses	90	0.01	− 0.08–0.09	0.892	0.05	− 0.06–0.16	0.362	49	0.04	− 0.08–0.16	0.530	0.05	− 0.06–0.16	0.390

Quick links

Search